Dabigatran (Pradaxa®)


Molecular mass 627,73 Da
Bioavailability 6,5 %
Peak concentration 2-3 hours after drug administration
Half-life 13 to 18 hours

Dabigatran is a direct, reversible thrombin inhibitor. The drug comes in form of dabigatran etexilate, which is pharmacologically inactive. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalyzed hydrolysis in plasma and liver.

Clinical significance

The following applications are indicated: primary prevention of venous thromboembolic events in adults after elective hip or knee replacement surgery, prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation with one or more risk factors, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as prevention of recurrent DVT and PE.


  • Routine monitoring is not necessary
  • The measurement of coagulation inhibition in combination with dabigatran may be useful to avoid excessive exposure to dabigatran in the presence of additional risk factors


  1. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 38(1):16-22, 2013.
  2. Cini M, Legnani C, Cosmi B, Testa S, Dellanoce C, Paoletti O, Marcucci R, Poli D, Paniccia R, Pengo V, Tripodi A, Palareti G. START-Laboratory RegisterComparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register. Int J Lab Hematol. 40(2):229-236, 2018.
Test kits
Clotting assay

Technoclot DTI


Calibration plasma

Calibration plasma Pradaxa®


Control plasma

Control plasma Pradaxa®


We are here for you

Haemochrom Diagnostica GmbH
Renteilichtung 1
45134 Essen

Phone: +49 (0)201 8 43 77-0
Fax: +49 (0)201 53 64 56

Send us a message